PRIMOMED

Use of PRIMate MOdels to support translational MEDicine and advance disease modifying therapies for unmet medical needs

Coordinatore	AMAKEM NV    more  Organization address address: AGORALAAN GEBOUW ABIS BIOVILLE city: DIEPENBEEK postcode: 3590 contact info Titolo: Dr. Nome: Jack Cognome: Veuskens Email: send email Telefono: 32496741166 Fax: 3211490209
Nazionalità Coordinatore	Belgium [BE]
Totale costo	1˙602˙769 €
EC contributo	1˙234˙000 €
Programma	FP7-SME Specific Programme "Capacities": Research for the benefit of SMEs
Code Call	FP7-SME-2013
Funding Scheme	BSG-SME
Anno di inizio	2014
Periodo (anno-mese-giorno)	2014-01-01   -   2015-09-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	AMAKEM NV  Organization address address: AGORALAAN GEBOUW ABIS BIOVILLE city: DIEPENBEEK postcode: 3590 contact info Titolo: Dr. Nome: Jack Cognome: Veuskens Email: send email Telefono: 32496741166 Fax: 3211490209	BE (DIEPENBEEK)	coordinator	320˙235.00
2	COMPLIX NV  Organization address address: AGORALAAN BUILDING A-BIS city: DIEPENBEEK postcode: 3590 contact info Titolo: Dr. Nome: Thore Cognome: Hettmann Email: send email Telefono: 3211286952	BE (DIEPENBEEK)	participant	374˙599.00
3	MIND-NRG SA  Organization address address: RUE DE JARGONNANT 2 city: GENEVE postcode: 1207 contact info Titolo: Mr. Nome: Bertrand Cognome: Damour Email: send email Telefono: 41793796118	CH (GENEVE)	participant	354˙550.00
4	FAST FORWARD PHARMACEUTICALS BV  Organization address address: YALELAAN 46 city: UTRECHT postcode: 3584 CM contact info Titolo: Mr. Nome: Mark Cognome: De Boer Email: send email Telefono: 31654311946	NL (UTRECHT)	participant	172˙616.00
5	FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V  Organization address address: Hansastrasse 27C city: MUENCHEN postcode: 80686 contact info Titolo: Ms. Nome: Andrea Cognome: Zeumann Email: send email Telefono: +49 89 1205 2723	DE (MUENCHEN)	participant	6˙000.00
6	STICHTING BIOMEDICAL PRIMATE RESEARCH CENTER  Organization address address: LANGE KLEIWEG 161 city: RIJSWIJK ZH postcode: 2288 GJ contact info Titolo: Prof. Nome: Bert Cognome: T Hart Email: send email Telefono: 31152842691	NL (RIJSWIJK ZH)	participant	6˙000.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'The focus of Primomed is the translational medicinal approach of the SMEs, i.e. developing disease modifying therapeutics for high unmet medical needs in chronic inflammatory and degenerative disorders. The Primomed project utilizes well characterized non-human primate models so that the SMEs can capitalize on subsequent clinical successes of their therapeutic lead compounds. The main objectives of the project are (1) to demonstrate proof of concept that drug compounds of the SME’s are efficacious in primate models relevant for the diseases of interest and (2) to determine the immune responses in biological samples generated by the research activities in the different animal models. The power of the Primomed project is the creation of a consortium bringing together four small and early-stage biotech companies owning innovative and proprietary drugs and two of the most renowned European primate research centres that will perform research activities with the new disease modifying molecules of the SME’s. The disease areas of interest in Primomed are asthma, multiple sclerosis and Parkinson disease. Amakem’s Localized Drug Action approach would allow the use of ROCK inhibitors for the treatment of respiratory diseases, e.g. asthma, while avoiding the side effects resulting from systemic ROCK inhibition. By selectively targeting IL-23p19, Complix’ Alphabody is an intriguing candidate for therapy development of asthma and MS and may avoid some of the severe side effects of other currently available and tested anti-IL12/IL23p40 therapies. FFP’s PG102 would be a first in class molecule with a novel mechanism of action in treating chronic inflammatory conditions such as MS. sNRG would be a protein drug with disease modifying potential for the treatment of an unmet medical need in Parkinson’s disease. Primomed will result in progressing the compounds to the clinic, maximize the chance at eventual market authorization and answer the unmet medical need of millions of patients.'